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In Brief
Elling et al. utilize a number of lincRNA-Cox2 genetic models to show that lincRNA-Cox2 can regulate its neighboring gene Ptgs2 (Cox2) through an enhancer RNA mechanism. They generate a lincRNA-Cox2 splicingdeficient mouse and confirm that lincRNA-Cox2 functions in trans to regulate immune genes following LPSinduced endotoxic shock. 
INTRODUCTION
Activation of myeloid cells is associated with differential expression of immune genes involved in host defense, tissue repair, and resolution of inflammation. Toll-like receptors (Tlrs) are germlineencoded receptors critical for the activation of signaling pathways controlling immune response genes. Dysregulation of these pathways can lead to deleterious autoinflammatory conditions, which can contribute to autoimmunity or cancer (Gajewski et al., 2013; Gierut et al., 2010; Masters et al., 2009) . Tight control of these inflammatory signaling cascades is required to prevent host damage and is achieved both transcriptionally and posttranscriptionally.
The majority of mammalian genomes are pervasively transcribed, producing thousands of noncoding RNAs (ENCODE Project Consortium, 2012) . Interestingly, the expression of these noncoding genes is highly cell type-specific (Morris and Mattick, 2014) , and their function remains largely unknown. Long intergenic noncoding RNAs (lincRNAs) are a subclass of long noncoding RNAs (lncRNAs) that form the largest class of RNA produced in the genome. The tremendous number of newly annotated lincRNAs and their low evolutionary conservation has led to debates about their functionality (Bassett et al., 2014) . However, the number of characterized lincRNAs is growing, and this class of gene has been shown to control various biological processes, including somatic tissue differentiation (Kretz et al., 2013) , X chromosome inactivation (Carmona et al., 2018; Engreitz et al., 2013; Jé gu et al., 2017) , and organ development (Anderson et al., 2016) .
LincRNAs function to control gene expression either in cis, where they influence the expression and/or chromatin state of neighboring genes, or in trans, where the lincRNA leaves the site of transcription and affects genes on different chromosomes (Kopp and Mendell, 2018; Liang et al., 2018; Neumann et al., 2018) . These trans-acting lincRNAs, such as FOXF1 adjacent non-coding developmental regulatory RNA (FENDRR), long-intergenic non-coding-erythroid prosurvival (linc-EPS), and Nettoie Salmonella pas Theiler's (NeST), can function to regulate chromatin states (Atianand et al., 2016; Gomez et al., 2013; Grote et al., 2013; Sauvageau et al., 2013) , influence nuclear structure and organization (Rinn and Guttman, 2014) , or interact with and regulate the behavior of proteins and/or other RNA molecules (Covarrubias et al., 2017; Kawasaki et al., 2018; Lee et al., 2016; Wang et al., 2017) .
lincRNAs have recently been shown to regulate the development and function of immune cells (Kotzin et al., 2016; Wang et al., 2014 Wang et al., , 2017 . Previous work from our lab and others defined an immune-inducible lincRNA, lincRNA-Cox2 (synonym Ptgs2os2) with broad trans-regulatory activity on inflammatory responses Covarrubias et al., 2017; Hu et al., 2016; Tong et al., 2016; Xue et al., 2018) . In macrophages, where this lincRNA was highly induced upon inflammatory activation, lincRNA-Cox2 functioned to activate and repress distinct classes of innate immune genes . However, like most lincRNAs and protein-coding genes, the cis-and trans-regulatory elements encoded within the locus remain unstudied in vivo. Most recently, some lincRNAs have been discovered to have the ability to function both in cis and in trans (Carmona et al., 2018; Li et al., 2012; Yin et al., 2015) .
Here we created a combination of different genetic deletion models to study the role of the lincRNA-Cox2 locus in macrophages and in murine models in vivo. Consistent with prior work, we found that lincRNA-Cox2-deficient macrophages had altered expression of numerous inflammatory genes Covarrubias et al., 2017) . In addition, we observed a profound cis function for lincRNA-Cox2: lincRNA-Cox2-deficient mice had severely reduced expression of the neighboring gene Ptgs2, a gene that encodes for cyclooxygenase-2 (Cox2), a central enzyme of the prostaglandin biosynthesis pathway, across several tissues. This finding provides evidence for a previously unrecognized cis function for lincRNA-Cox2. We have data that support lincRNA-Cox2 functioning through an RNA-mediated mechanism as an enhancer RNA (eRNA) to regulate Ptgs2 expression. Crossing our lincRNA-Cox2-deficient mice to wild-derived mice (MOLF) that have a distinct genetic background provides critical evidence that lincRNA-Cox2 indeed functions on the same chromosome to regulate Ptgs2 expression levels.
Finally, to distinguish the cis-regulatory element from the trans activity of the RNA transcript, we generated a ''mutant'' mouse model that retained the exonic sequences of the lincRNA but lacked the intron and splicing capabilities. This resulted in a mouse with a low basal expression level of lincRNA-Cox2, but the transcript is no longer inducible following inflammatory stimulation. In the mutant mouse, Ptgs2 expression is comparable with wild-type mice as the eRNA activity of the lincRNA-Cox2 locus is maintained. Using a conventional in vivo lipopolysaccharide (LPS) shock model, we identify an additional role for the lincRNA-Cox2 transcript in the trans regulation of a subset of immune genes as well as an organ-specific role independent of Ptgs2 biology. Collectively, these observations reveal a bimodal action of gene regulation by the lincRNA-Cox2 transcript: a trans-regulatory function controlling immune genes such as cytokines globally and a separate enhancer function acting to regulate prostaglandin biosynthesis via Ptgs2 (Cox2). Thus, lincRNA-Cox2 represents a regulator of the Ptgs2 pathway as well as an important mediator of immunity beyond the prostaglandin pathway.
RESULTS
Genetic Deletion of lincRNA-Cox2 Alters Immune Gene Expression in Macrophages
LincRNA-Cox2 is encoded on chromosome 1 and transcribed from the negative strand. The mature sequence has 2 exons and is 1.7 kb long. Its nearest protein coding gene, prostaglandin-endoperoxide synthase 2 (Ptgs2 or Cox2), is 50 kb upstream and transcribed on the positive strand ( Figure 1A) . A lincRNA-Cox2 knockout (KO) mouse was generated by removing the entire genomic locus (5.9 kB), except for the promoter, and replacing it with a LacZ reporter cassette (Sauvageau et al., 2013; Figure 1B) . KO mice were born at expected Mendelian frequencies with no obvious developmental abnormalities (Sauvageau et al., 2013) . We and others have previously published that lincRNA-Cox2 acts to positively and negatively regulate the expression of distinct classes of innate immune genes Covarrubias et al., 2017; Hu et al., 2016; Tong et al., 2016; Xue et al., 2018) . In those studies, short hairpin RNA (shRNA)-based knockdown of lincRNA-Cox2 reduced the levels of pro-inflammatory cytokines like Interleukin-6 (Il6) in bone-marrow derived macrophages (BMDMs) activated with LPS, whereas a number of interferonstimulated genes (ISGs) were expressed at higher levels. Here, using genetic approaches, we find that lincRNA-Cox2-deficient BMDMs ( Figure 1C ) produced less Il6 ( Figure 1D ) and more Chi3L as well as IfI202b, an ISG, following LPS (Tlr4) and R848 (Tlr7) stimulation (Figures 1E and 1F) .
Ptgs2 Levels Are Reduced in lincRNA-Cox2 KO Mice The lincRNA-Cox2 KO mouse was generated so that the locus remains transcriptionally active and LacZ staining can be used as a surrogate for lincRNA-Cox2 expression (Sauvageau et al., 2013) . Staining of several organs from these mice revealed the in vivo expression of lincRNA-Cox2 in both the brain (dorsal cerebral cortex) and the lung under steady-state conditions (Figure 2A ). Further, RNA sequencing (RNA-seq) from a variety of organs confirmed that lincRNA-Cox2 was most highly expressed in the lung at steady state ( Figure S1A ). To identify the target genes of lincRNA-Cox2 at steady state, we performed RNA-seq on whole lung tissue, comparing wild-type and lincRNA-Cox2-deficient mice. Using differential expression sequencing 2 (DESeq2) with a cut off of 2.5-fold and a p value of 0.05, 476 genes showed altered expression (273 were upregulated and 203 were downregulated) (Table S1 ). Among the most significantly downregulated genes was Ptgs2 (Figure 2B, highlighted in red) .
Next we wanted to investigate the lincRNA-Cox2 locus at higher resolution and across different tissues to understand whether this effect was specific to Ptgs2 or whether the genetic manipulation of the locus altered other neighboring genes. To that end, we compared the transcriptomes from WT and KO animal brains and lungs and generated cis region plots spanning a 1-Mb window in the vicinity of the lincRNA-Cox2 locus. In both the lung and brain, which have high expression of lincRNA-Cox2 represented by LacZ staining in organs from KO mice (Figure 2A ), the only gene affected in this region at steady state was Ptgs2 ( Figures S2A and S2B ). To determine whether the cis effect on Ptgs2 persisted after an inflammatory stimulus in vivo, a context in which the lincRNA transcript is highly induced, we measured the expression of Ptgs2 in the lung, spleen, and liver following intraperitoneal (i.p.) injection of E. coli LPS (20 mg/kg) for 6 hr. In WT mice, lincRNA-Cox2 and Ptgs2 were inducible in the spleen and liver (Figures 2C-2G) following LPS treatment. Ptgs2 levels were reduced in all tissues examined from lincRNA-Cox2 KO mice following LPS challenge ( Figures  2D-2H ). LacZ expression remained comparable with lincRNA-Cox2 expression in the tissues from KO mice following LPS treatment, confirming that the locus is actively transcribed (Figures S2C and S2D) .
We also examined Ptgs2 levels in BMDMs from the lincRNA-Cox2 KO mice following stimulation with various Tlr ligands. In each case, the inducible transcriptional expression of Ptgs2 was greatly reduced ( Figure 2I ). We confirmed this effect at the protein level in lincRNA-Cox2-deficient BMDMs by immunoblotting for Ptgs2 ( Figure 2J ). Ptgs2 is the central enzyme of the pros-taglandin pathway catalyzing the conversion of arachidonic acid to prostaglandins (Ricciotti and FitzGerald, 2011) . Consistent with the reduced expression of Ptgs2 RNA and protein, there was reduced pro-inflammatory prostaglandin E2 (PGE2) production in lincRNA-Cox2-deficient cells as measured by mass spectrometry ( Figure 2K ). Together, all of these data indicate that the lincRNA-Cox2 locus controls the expression of Ptgs2 and, therefore, prostaglandin biosynthesis.
Rescue of Mature lincRNA-Cox2 Fails to Restore Inducible Ptgs2 Expression in Macrophages LincRNA-Cox2 and Ptgs2 show parallel inducible expression kinetics following Tlr activation. In prior work, we showed that knocking down the lincRNA transcript using shRNA had no effect on the expression of Ptgs2 . This observation contrasts with the strong cis effect of the lincRNA locus observed in our KO model and could be consistent with a DNA-mediated enhancer effect, a mechanism that has previously been reported for other lincRNA loci (Engreitz et al., 2016; Groff et al., 2016; Joung et al., 2017; Paralkar et al., 2016) . To gain more insight into the molecular basis for this cis effect, we reconstituted lincRNA-Cox2-deficient primary BMDMs with the full-length spliced mature RNA transcript (Figure 3A) via plasmid electroporation. Despite restoration of lincRNA-Cox2 to a level of expression comparable with that seen in wild-type (WT) cells, Ptgs2 expression could not be rescued ( Figure 3B ). To control for possible effects mediated by knockin of the LacZ transgene, we also generated a BMDM line lacking lincRNA-Cox2 using CRISPR/Cas9 to validate these findings. We designed guide RNAs to the 5 0 and 3 0 ends of the lincRNA-Cox2 gene as outlined in Figure 3C , using two guide RNAs that remove the entire locus encoding the gene (while leaving the promoter intact). KO of lincRNA-Cox2 was confirmed by qRT-PCR ( Figure 3D ). Ptgs2 levels were also impaired in these Cas9-edited cells ( Figure 3E ). Again, reconstitution 152,006,500 152,007,000 152,007,500 152,008,000 152,008,500 152,009,000 152,009,500 152,010,000 152,010,500 152,011,000 152,011,500 152,012,000 152,012,500 152,013,000 152,013,500 152,014,000 with the full-length lincRNA-Cox2 transcript by lentiviral expression, which localized to both the nuclear and cytoplasmic compartments ( Figures S3A and S3B ), failed to rescue this phenotype ( Figures 3F and 3G ).
lincRNA-Cox2
Functions through an eRNA Mechanism to Regulate Ptgs2 Recently, it has been shown that non-coding RNA loci have the potential to harbor enhancer activities (Engreitz et al., 2016; Groff et al., 2016; Kim et al., 2015; Kotzin et al., 2016; Melo et al., 2013; Paralkar et al., 2016; Ørom et al., 2010) . Because the effect of lincRNA-Cox2 deficiency on Ptgs2 levels was not rescued by ectopic expression, we speculated that the lincRNA-Cox2 locus harbored a DNA enhancer element controlling Ptgs2 expression. LincRNA-Cox2 possesses two exons, with the majority of the sequence lying within exon 2. Using CRISPR/Cas9, we excised exon 2 from lincRNA-Cox2 in BMDMs ( Figure 3H ) and confirmed this deletion by qRT-PCR ( Figure 3K ). Ptgs2 was measured by qRT-PCR, and expression was markedly reduced in the exon 2 KO BMDMs, again suggesting that either the lincRNA transcript or a DNA enhancer element within exon 2 is required for the activity on Ptgs2 ( Figure 3L ). These data confirm that there is no enhancer activity lying within exon 1, which remains intact in this model. To determine whether there are any enhancer marks present within exon 2 of lincRNA-Cox2, we studied chromatin immunoprecipitation sequencing (ChIP-seq) of histone marks associated with enhancers, including histone 3 lysine 4 (H3K4) mono-methylation, as well as p300 binding from the Mouse Encode project and from Lara-Astiaso et al. (2014) and Stamatoyannopoulos et al. (2012) . We were surprised that there was no evidence of any enhancer within exon 2 of lincRNA-Cox2 and, instead, enhancer marks were identified upstream of the transcription start site of lincRNA-Cox2 ( Figure 3I ; Figure S4 ). These data suggest that this locus might function instead as an eRNA in which transcription of lincRNA-Cox2 functions to connect the enhancer region with the Ptgs2 locus to drive expression of the protein. The enhancer region within the lincRNA-Cox2 promoter remains intact in the KO mouse, and the locus is transcriptionally active, but there is a strong defect in Ptgs2 levels. Only the lincRNA-Cox2 transcript is absent in this model, and because there are no identifiable enhancer elements within this region, it suggests that specific transcription of the lincRNA-Cox2 sequence is driving this phenotype as an eRNA.
To test whether lincRNA-Cox2 can function as an eRNA, we used CRISPR interference (CRISPRi) as outlined in Figure 3J to inhibit transcription of the locus. We successfully knocked down lincRNA-Cox2 by over 95% using two independent guide RNAs in a clonal cell line ( Figure 3M ), and each led to a more than 95% decrease in Ptgs2 expression, as assayed using qRT-PCR ( Figure 3N ). This result was replicated in a second CRISPRi BMDM cell line ( Figures S5C and S5D) . These data strongly indicate that it is locus-specific transcription of lincRNA-Cox2 and not a DNA element within the exonic sequence of the gene that is critical to its function to control Ptgs2 levels.
To determine whether lincRNA-Cox2 regulates Ptgs2 on the same chromosome, one final experiment was performed using mice with distinct genetic backgrounds. We took advantage of the wild-derived mouse strain MOLF, which is genetically distinct from the common laboratory C57/Bl6 mice. MOLF mice possess numerous SNPs that are distinct compared with C57/Bl6 mice (Doran et al., 2016) . Within the last exon of Ptgs2, MOLF mice have 5 distinct SNPs that can be used to distinguish the C57/ Bl6 and MOLF alleles. As outlined in Figure 4A , we crossed WT C57/Bl6 or lincRNA-Cox2 KO C57/Bl6 mice with MOLF-WT mice to determine how loss of lincRNA-Cox2 affects Ptgs2. By qRT-PCR, we show that lincRNA-Cox2 expression is lost in the KO mice, whereas the native promoter is intact, represented by LacZ expression ( Figures 4B and 4C) . When examining the heterozygous mice, the MOLF-KO mice had reduced expression of lincRNA-Cox2 and Ptgs2 compared with MOLF-WT mice (Figures 4B and 4D) . Using RNA-seq, we determined that only the lincRNA-Cox2 KO allele (C57/Bl6) had decreased expression of Ptgs2. The MOLF-WT allele, which has an intact lincRNA-Cox2 gene, was unaffected by the loss of lincRNA-Cox2 ( Figures  4E and 4F) . These results support the finding that lincRNA-Cox2 functions to regulate the expression of Ptgs2 on the same chromosome and is graphically summarized in Figure 4G .
Ptgs2 Expression Is Not Required for Transcriptional Activity of lincRNA-Cox2
Because lincRNA-Cox2 and Ptgs2 show parallel expression kinetics following an inflammatory stimulus , we wanted to explore whether the regulatory interaction between lincRNA-Cox2 and Ptgs2 was unidirectional or whether Ptgs2 itself affects the expression levels of the lincRNA. In addition, we wanted to understand whether the effect on Ptgs2 was responsible for the changes in inflammatory genes, such as Il6.
To address this question, we crossed conditional Ptgs2 flox/ flox mice (Wang et al., 2009) to Vavi-Cre mice to delete Ptgs2 in all hematopoietic cells. We generated BMDMs from these immunoblotting and qRT-PCR in BMDMs stimulated with LPS ( Figures 5A and 5B) . The induction of lincRNA-Cox2 proceeded normally in Ptgs2-deficient BMDMs ( Figure 5C ). Importantly, the induction of Il6 and Ifi202b, which were both affected by lincRNA-Cox2 deficiency, was normal in Ptgs2-deficient cells ( Figures 5D and 5E ). Together, these results suggest that the lincRNA-Cox2 transcript can regulate genes in trans that are not normally regulated by Ptgs2. Thus, lincRNA-Cox2 may represent an important modulator within and outside of the Ptgs2 pathway.
Additionally, we used the BMDM CRISPRi clonal cell lines to target Ptgs2 using two independent guide RNAs, as represented in Figure 5F . CRISPRi-mediated knockdown of Ptgs2 by more than 90% had no effect on the transcription of lincRNA-Cox2 upon LPS stimulation. These data further confirm that Ptgs2, RNA or protein, is not necessary for transcriptional activity of lincRNA-Cox2 basally or after inflammatory stimulation ( Figures  5G and 5H; Figures S6C and S6D) , whereas lincRNA-Cox2 is required for Ptgs2 expression.
A lincRNA-Cox2 Splicing Mutant Mouse Fails to Produce Any Inducible lincRNA-Cox2 Transcript To determine the trans functions of this lincRNA transcript independent of its role in regulating Ptgs2, we generated a mouse model with a deletion of the 2.3-kb intronic region utilizing CRISPR/Cas9 (hereafter referred to as mutant mice). We designed two guide RNAs targeting the 5 0 and 3 0 splice sites of lincRNA-Cox2. Exon 2 remained completely intact, whereas 50 bp were deleted from exon 1 ( Figure 6A ). PCR genotyping confirmed the mutant as described in Figure 6B . These mice were also born at expected Mendelian frequencies with no obvious developmental abnormities. We generated BMDMs from the mutant mice and examined the expression of lincRNA-Cox2 in response to LPS challenge. Although the lincRNA-Cox2 transcript was inducible following LPS stimulation in WT BMDM cells, there was only very low basal expression of lincRNA-Cox2 in the mutant BMDM cells, as measured by qRT-PCR ( Figure 6C) .
In contrast to data we obtained with the full gene KO, Ptgs2 levels were comparable between the WT and mutant BMDMs ( Figure 6D ). We next examined Ptgs2 levels in tissues, specifically the lung, where lincRNA-Cox2 is most highly expressed, and the spleen, where the majority of white blood cells are stored (Figures 2A, 2C, and 2E, Figure S1A ). In the mutant, intron-less mouse, lincRNA-Cox2 levels were dramatically reduced in the lung and spleen following LPS stimulation (Figures 6E and 6G) . Again, there was no effect on Ptgs2 levels within the lung and spleen of mutant mice (Figures 6F and  6H) . These observations support the hypothesis that this locus can function as an enhancer to regulate Ptgs2 and that this eRNA activity is maintained in this model. The enhancer located prior to the start site of the locus in conjunction with the basal transcript work together to mediate these effects on Ptgs2.
lincRNA-Cox2
Regulates Distinct Sets of Genes in the Lung and Spleen Now having two separate mouse models, a complete deletion KO mouse, and an intron-less mutant mouse, we asked whether the absence of the lincRNA-Cox2 transcript has a trans and organ-specific role in vivo. lincRNA-Cox2 is expressed at high levels in the lung and very low in the spleen (Figures 2D and  2E ; Figure S1A ). The expression of lincRNA-Cox2 is inducible upon LPS challenge in the spleen and slightly reduced in the lung (Figures 2D and 2E) . To define the global regulatory role of lincRNA-Cox2, we challenged WT, KO, and mutant mice by i.p. injection of E. coli LPS for 6 hr, followed by RNA-seq of the spleen and lung, as represented in Figure 6I . DESeq2 analysis was used to determine the differentially expressed (DE) genes between WT versus KO, WT versus mutant, or KO versus mutant in both the lung and spleen ( Figure 6J ). The KO versus WT mice had 312 DE genes in the lung and 313 DE genes in the spleen ( Figure 6J ). The mutant versus WT mice had 115 DE genes in the lung and 179 DE genes in the spleen ( Figure 6J) . When comparing gene expression of mutant mice with KO mice, there were hundreds of significantly DE genes, reinforcing that these mice had very distinct phenotypes from one another because of the cis and trans functions of lincRNA-Cox2 (Figures 6J-6L) . Interestingly, when comparing mutant lincRNA-Cox2-specific DE genes, there are only six that overlap between the spleen and lung ( Figure 6M ). Of these six genes, only one gene changed from being upregulated to downregulated from the spleen to the lung, Ptprh (synonym Sap-1) ( Figure S7C ; Bujko et al., 2017) . Database for Annotation, Visualization, and Integrated Discovery (DAVID) analysis of the differentially expressed genes of the spleen and lung show similar pathways, such as glycoprotein and inflammatory response, as well distinct pathways, such as fibronectin and heparin binding in the spleen or cellular homeostasis and secretory granule pathways in the lung (Figures S7A and S7B) . LincRNA-Cox2 is highly expressed in the lung in a very cell type-specific manner (Figures S1B and S1C). Using the Mouse Cell Atlas generated by Han et al., 2018 , we can show the differences in cell type expression between Ptgs2 and lincRNA-Cox2 ( Figure S1B ). Overall, lincRNA-Cox2 has a higher expression in specific immunerelated cells in the lung, whereas Ptgs2 has higher expression in epithelial and endothelial cells, providing additional evidence that lincRNA-Cox2 has distinct roles in trans independent of its regulation of Ptgs2.
lincRNA-Cox2 Controls Immune Genes in trans
Independent of Ptgs2 following LPS Challenge In Vivo The generation of the mutant intron-less lincRNA-Cox2 lossof-function model allowed us to assess the contribution of the lincRNA transcript in vivo independent of the cis effect on Ptgs2. We asked whether the absence of the lincRNA-Cox2 transcript affects in vivo responses to LPS. We challenged the lincRNA-Cox2 mutant mice in vivo by i.p. injection of E. coli LPS. The temperature of the mice, a clinical parameter of septic shock, decreased over time in both strains ( Figure 7A ). Serum cytokines were then measured using multiplex assays. Interferon-stimulated genes, including Ccl5 (Rantes) and Ip10, were both found at elevated levels in the lincRNA-Cox2 mutant mice following LPS challenge ( Figures 7B and 7C) , whereas proinflammatory gene expression, including Il5, Lif, and Il17, was reduced ( Figures 7D-7F) . Tnfa expression levels were unchanged in control and mutant mice ( Figure 7G ). These in vivo data are consistent with published in vitro data showing that lincRNA-Cox2 can act to both promote and inhibit the expression of innate immune genes. Because all genes affected in the mutant mice were located on different chromosomes to lincRNA-Cox2 (chromosome 1), these data confirm that lincRNA-Cox2 functions in trans to control immune responses in vivo.
DISCUSSION
lincRNAs remain an understudied class of genes specifically in the context of the immune system. Although there are a number of studies, both by our lab and others, showing that lincRNA-Cox2 promotes and restrains different classes of innate immune gene expression, none have shown the function of this gene in vivo Covarrubias et al., 2017; Hu et al., 2016; Tong et al., 2016; Xue et al., 2018) . Here we expand our knowledge of the role of lincRNA-Cox2 by generating two murine models and multiple macrophage cell lines, which strengthens our earlier findings that lincRNA-Cox2 can inhibit expression of ISGs and enhance pro-inflammatory gene expression. In addition, we now reveal that lincRNA-Cox2 also functions through an eRNA mechanism to control the expression of the neighboring gene Ptgs2 (Cox2) in vivo.
We initially characterized the lincRNA-Cox2 KO mouse, generated by replacing the locus with LacZ, by tracking LacZ expression in organs after LPS challenge. We observed that lincRNA-Cox2 was highly expressed in the lung, and further analysis of RNA-seq data confirmed this observation.
To determine how loss of lincRNA-Cox2 expression affects gene expression at steady state, we performed RNA-seq on lung samples comparing WT and KO. We were intrigued to identify Ptgs2 among the most significantly altered transcripts in the KO lung. Our previous work using shRNA-mediated knockdown of lincRNA-Cox2 had not revealed any change in the expression levels of Ptgs2 in BMDMs , suggesting that this cis activity was carried out through an enhancer within the DNA of this locus. We were unable to rescue the expression of Ptgs2 by ectopic overexpression of lincRNA-Cox2, further suggesting that it is either the DNA responsible for the phenotype or that locus-specific expression of the transcript is required for this function. A caveat with the reconstitution experiment is that we express lincRNA-Cox2 off a plasmid using an EF1a promoter. Although the reconstituted lincRNA-Cox2 localizes to the nucleus and cytoplasm in a similar manner as the native transcript, it is no longer induced by its native promoter or undergoing splicing. Additional experiments, including ectopic expression of lincRNA-Cox2 with the native promoter or the entire locus, could help determine whether these features are critical for the function of lincRNA-Cox2 in controlling Ptgs2 in cis. The majority of the sequence for lincRNA-Cox2 lies within exon 2, and removing this exon using CRISPR resulted in a dramatic decrease in Ptgs2. However, when we examined the locus for enhancer elements, we did not identify any within exon 2 of the gene. Instead, we observed evidence for DNA enhancer elements that lie only within the promoter of lincRNA-Cox2, including H3K4 mono-methylation (H3K4me1) and p300 ChIP-seq. Interestingly, this enhancer region remained intact in the lincRNA-Cox2 KO mouse, and the locus was transcrip-tionally active, but Ptgs2 was downregulated. This indicates that locus-specific transcription of lincRNA-Cox2 is required to mediate the activity in cis, suggesting that lincRNA-Cox2 functions as a form of eRNA.
It has been reported that many lincRNAs act locally, explaining why lincRNAs, like lincRNA-Cox2, display a similar expression pattern as their neighboring protein-coding genes. A recent study by Engreitz et al. (2016) showed that lncRNA and protein-coding genes can function locally and affect each other's expression levels. They show that 5 of 12 lincRNA loci they studied affected their neighboring gene in cis either through enhancer activity from within the promoter through the act of transcription or the act of splicing of the lincRNA (Engreitz et al., 2016) . eRNAs are produced from transcriptionally active enhancer regions, which are epigenetically defined by high levels of H3K4me1, low levels of H3K4 trimethyl (H3K4me3), and high levels of histone 3 lysine 27 acetylation (H3K27Ac) (Creyghton et al., 2010; Heintzman et al., 2007; Visel et al., 2009) . lincRNAs that function in cis to either enhance or suppress the expression of neighboring protein-coding genes can be classified as enhancer or repressor RNAs. Studies from IIott et al., 2014 identified over 40 canonical lincRNAs that act as eRNAs to regulate protein-coding genes upon LPS stimulation in human monocytes. Interestingly, although we found that knocking out lincRNA-Cox2 greatly affected Ptgs2, deletion of Ptgs2 itself did not affect basal or inducible levels of lincRNA-Cox2, showing that the effects are not reciprocal between these two loci. This result was further confirmed using CRISPRi, which mediates heterochromatin formation and silencing of gene transcription. Knocking down the transcription of Ptgs2 by over 90% had no effect on the regulation of lincRNA-Cox2. The lincRNA-Cox2 locus has both high H3K4me1 and H3K4me3 marks, making it distinct from the typical definition of eRNAs. It is possible that, as the field and function of lncRNAs continues to grow, that the categories that define their functions will also expand.
To determine whether transcription of lincRNA-Cox2 is important to regulate Ptgs2, we knocked down expression of the gene using CRISPRi. Our data show that we can knock down lincRNA-Cox2 expression more than 95%, which equally affects Ptgs2 expression by more than 95%. In addition, using active Cas9, we knocked out exon 2 of lincRNA-Cox2 (the majority of the lincRNA-Cox2 sequence), this perturbation also affected Ptgs2 expression. Because we did not identify any possible enhancer marks within exon 2, and all of the enhancer marks were within the promoter, we conclude that lincRNA-Cox2 is functioning through an eRNA mechanism to control Ptgs2. Although unlikely, it is possible that there is an unidentified enhancer mark within the DNA of exon 2. Future work aimed at inserting stop cassettes within exon 2 could confirm that, indeed, transcription of the gene is essential for Ptgs2 levels. The data we generated from our ''intron-less splicing mutant'' mice strongly suggest that this is the case. We used CRISPR/Cas9 to generate the mutant mouse. In this mouse, the exons of the lincRNA-Cox2 transcript are maintained; however, the intron and splice sites are removed. This mouse expressed basal levels of lincRNA-Cox2; however, the transcript is no longer inducible following LPS stimulation. It is possible that, because this transcript is no longer undergoing splicing, that it is highly unstable and, therefore, rapidly degraded following LPS stimulation. In the future, northern blots should be performed to confirm there are no additional unexpected lincRNA fragments in this model. Effectively, this mouse functions as a transcript loss-of-function mouse model of lincRNA-Cox2. Our studies with BMDMs and mice in vivo suggest that splicing is not required for the observed effect on Ptgs2. Low basal expression of the spliced lincRNA-Cox2 transcript is sufficient to activate the Ptgs2 locus, further suggesting that, indeed, this gene can function through an eRNA mechanism.
A final experiment was performed to assess whether lincRNA-Cox2 is regulating Ptgs2 on the same chromosome. We crossed our C57/Bl6 WT and KO mice with MOLF mice, which contain millions of SNPs, allowing us to differentiate between the two alleles. Studying the Ptgs2 locus, we found that only expression from the cis (C57/Bl6) allele was affected when lincRNA-Cox2 was knocked out. These data confirmed that indeed lincRNA-Cox2 functions to regulate Ptgs2 on the same chromosome. We predict that lincRNA-Cox2 is functioning as an eRNA and the RNA is tethering the enhancer to the Ptgs2 locus and forming a topologically associating domain. Further work including performing 3C/Hi-C should confirm this.
The lincRNA-Cox2 mutant mice are a critical model enabling us to study the trans activity for lincRNA-Cox2 independent of its effects on Ptgs2. As mentioned previously, this mouse functions as a transcript loss-of-function mouse model of lincRNA-Cox2. The original lincRNA-Cox2 KO mouse not only attenuated the expression of lincRNA-Cox2 but also repressed the expression of Ptgs2, whereas this model only affects lincRNA-Cox2 levels, enabling us to use these models to distinguish between the cis and trans functions for this gene.
Distinct tissue-specific functions have been shown for several lincRNAs. One such example is NEAT1, which is critical for synapse formation in the brain (Sunwoo et al., 2017) , whereas, in adipose tissue, NEAT1 is necessary for the differentiation of white adipocytes (Cooper et al., 2014) . lincRNA-Cox2 KO and mutant mice were used to globally study the cis and trans role of lincRNA-Cox2 in vivo by performing RNA-seq on lungs and spleens from LPS-challenged WT, KO, and mutant mice. Not surprisingly, we observed over 300 genes that were differentially regulated when comparing KO with WT mice, whereas only half that number were affected when comparing mutants with the WT. We believe that this is due to the fact that the mutant mice reveal only the functions of lincRNA-Cox2 in trans, whereas the KO mice exhibit both cis effects on Ptgs2 and trans effects.
Interestingly, the mutant mice possessed differentially expressed genes in the lung and spleen, emphasizing a possible organ-specific role for lincRNA-Cox2. Indeed, we observe very high levels of lincRNA-Cox2 in the lung, whereas the transcript is only induced in the spleen following inflammatory stimulation. Further work will be needed to understand mechanistically how lincRNA-Cox2 affects inflammatory responses in the lung and spleen. From our LacZ staining within the lung, combined with data from the mouse cell atlas, we observe cell type-specific expression patterns for lincRNA-Cox2. In the future, it will be informative to isolate these specific cells for further mechanistic studies.
Finally, we wanted to determine whether lincRNA-Cox2 can affect gene expression in the periphery following LPS challenge in vivo. We observe an increase in Ccl5 and Ip10 (Cxcl10) levels and a decrease in Il5, Il17, and Lif levels in the serum of mice following endotoxic shock, suggesting that lincRNA-Cox2 can function in trans to control various innate immune genes. These data highlight two important features of this lincRNA's function: the in vivo immune-regulatory activity of lincRNA-Cox2 on immune gene expression and the role of the lincRNA-Cox2 locus in controlling Ptgs2 (Cox2) levels. Together, these studies further our understanding of how lincRNAs can function both in cis and in trans to control gene expression, findings that are only evident through the use of multiple complimentary genetic perturbations. The drastic influence of non-coding genes on key immune signaling axes, such as the prostaglandin pathway as shown here, has broad translational implications because it indicates that protein-centered sequencing approaches are likely insufficient to fully understand genetically mediated autoimmune and auto-inflammatory conditions. Large-scale functional validations of noncoding mutations, facilitated by CRISPR/Cas9, will provide a promising approach to better understand the pathogenesis of inflammatory and non-inflammatory diseases. CRISPR/Cas9 technology has revolutionized the field of genome editing and will be a critical tool moving forward to enable rapid generation of animal models to fully characterize any lincRNA locus.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: Fisher) . For RT-qPCR, 500-1000 ng were reversely transcribed (iScript Reverse Transcription Supermix, Biorad) followed by RT-PCR (iQ SYBRgreen Supermix, Biorad) using the cycling conditions as follows: 50 C for 2 min, 95 C for 2 min followed by 40 cycles of 95 C for 15 s, 60 C for 30 s and 72 C for 45 s. The melting curve was graphically analyzed to control for nonspecific amplification reactions.
RNA-Sequencing
For generation of RNA-Sequencing libraries, RNA was isolated as described above and the RNA integrity was tested with a BioAnalyzer (Agilent Technologies) or FragmentAnalyzer (Advanced Analytical). For RNA-Sequencing target RIN score of input RNA (500-1000ng) usually had a minimum RIN score of 8. RNA-Sequencing libraries were prepared with TruSeq stranded RNA sample preparation kits (Illumina), depletion of ribosomal RNA was performed by positive selection of polyA+ RNA. Sequencing was performed on Illumina HighSeq or NextSeq machines. RNA-seq 50bp reads were aligned to the mouse genome (assembly GRCm38/mm10) using TopHat. The Gencode M13 gtf was used as the input annotation. Differential gene expression specific analyses were conducted with the DESeq R package. Specifically, DESeq was used to normalize gene counts, calculate fold change in gene expression, estimate p values and adjusted p values for change in gene expression values, and to perform a variance stabilized transformation on read counts to make them amenable to plotting. Data was submitted to GEO GSE117379.
MiSeq
For the MOLF experiment, 5ul of cDNA from MOLF-WT or MOLF-KO (2 mice each) was used to template a PCR reaction using 1uM of primers: Ptgs2lastexon_fwd: gaaCCAcctTGTTGGACAGGAGAGAAGGAAATGGC and Ptgs2lastexon_rev: CCAGCTTAGCCGCCT TTTGATTAGTACTGTAGGG and using the following cycle parameters: 1x (98C for 30 s), 20x (98C for 15 s, 56C for 15 s, 72C for 30 s) and 1x (72C for 10 min) using phusion 2X master mix (ThermoFisher, F0531). PCR products (MOLF-WT, MOLF-WT, MOLF-KO, MOLF-KO) were purified using Macherey-Nagel Gel-extraction columns, were digested with BstXI/Blp and were ligated into pU6-sgRNA vector (https://benchling.com/s/CXQ8OiQn/edit) (gift from the Weissman Lab, UCSF) using standard T4 ligase. Ligation was transformed, and coverage was determined to be > 200 colonies for each ligation. Using 1ul of the ligation reaction, we template a second PCR reaction using 1uM of the custom illumina primers (Liu et al., 2017) . Using the following cycle parameters: 1x (98C for 30 s), 20x (98C for 15 s, 56C for 15 s, 72C for 30 s) and 1x (72C for 10 min). PCR products were gel extracted on a 1% agarose gel and were purified using Macherey-Nagel Gel-extraction columns. Amplicons were sequenced on the MiSeq using the custom sequencing. For each sample, counts were generated for MOLF or C57/Bl6 Ptgs2 alleles respectably using sequences: and were normalized to total reads for analysis. Data was submitted to GEO GSE117379.
Measurement of prostaglandins by mass spectrometry
Prostaglandin E2 production was measured by liquid chromatography/mass spectrometry as previously described 16 . Briefly supernatants were collected from Wild-Type or KO BMDMs following LPS stimulation for 6h. Systemic production of PGE 2 , determined by quantifying the major urinary metabolites 7-hydroxy-5, 11-diketotetranorprostane-1, 16-dioic acid (PGEM). Results were normalized with creatinine.
Western Blot Analysis
For western blotting, BMDMs were scraped, washed and lysed buffer containing 20mM Tris-HCl (pH 7.4), 1% NP-40 and 5mM EDTA supplemented with Protease inhibitor (Promega). Clarified samples were separated by SDS-PAGE and transferred to PVDF membranes using the Trans-Blotâ Turbo Transfer System (BioRad). After blocking of the PVDF membrane with PBS containing 5% (w/v) skim-milk powder and 0.1% Tween-20, the blots were probed with anti-COX2 (Cayman Item #160106) or anti-Actin (Sigma) antibodies. Visualization was performed with enhanced chemiluminescence substrate (ECL Pierce).
LacZ staining
For detection of reporter gene expression in lincRNA-Cox2 deficient mice, selected tissue was dissected and fixed in 4% paraformaldehyde (PBS) for 5 hours (4 C). Fixed tissues were washed 3x with wash buffer (2mM MgCl 2 , 0,01%sodium deoxycholate, 0,02% NP-40) and subsequently incubated in staining buffer (1mg/ml X-Gal, 5mM potassium ferricyanide, 5mM potassium ferrocyanide, 2mM MgCl 2 , 0.01% sodium deoxycholate, 0.02% NP-40) in the dark overnight (room temperature). Staining solution was rinsed off with PBS 3x and tissue were frozen in OCT on dry ice and sectioned in 10mm sections.
QUANTIFICATION AND STATISTICAL ANALYSIS
For in vivo studies All in vivo studies were carried out using n R 5. In every figure, each dot represents an individual animal. Student's t tests were performed using GraphPad Prism7. Asterisks indicate statistically significant differences between mouse lines (* = > 0.05, ** = > 0.01 and *** = > 0.005).
For in vitro studies Data represents 3 combined biological replicates, representative of 3 individual experiments. Student's t tests were performed using GraphPad Prism7. Asterisks indicate statistically significant differences between mouse lines (* = > 0.05, ** = > 0.01 and *** = > 0.005).
DATA AVAILABILITY
All sequencing data generated from Mi-Seq and RNA-seq reported in this paper have been deposited to GEO under the ID code GSE117379.
